These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 24060287

  • 1. Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
    Parker SM, Hyder MA, Fesler MJ.
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e15-7. PubMed ID: 24060287
    [No Abstract] [Full Text] [Related]

  • 2. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
    García Muñoz R, Izquierdo-Gil A, Muñoz A, Roldan-Galiacho V, Rabasa P, Panizo C.
    Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
    [Abstract] [Full Text] [Related]

  • 3. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
    Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K, Japanese Bendamustine Lymphoma Study Group.
    Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
    [Abstract] [Full Text] [Related]

  • 4. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
    Rummel MJ.
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
    [Abstract] [Full Text] [Related]

  • 5. [Alleviated anemia by bendamustine in cold agglutinin disease associated with small lymphocytic lymphoma].
    Kuno M, Inoue A, Aimoto M, Nakao T, Kameda K, Yoshida M, Kanashima H, Hirai M, Yamane T.
    Rinsho Ketsueki; 2015 Feb; 56(2):204-9. PubMed ID: 25765801
    [Abstract] [Full Text] [Related]

  • 6. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW, Kolesar JM.
    Clin Ther; 2009 Feb; 31 Pt 2():2290-311. PubMed ID: 20110042
    [Abstract] [Full Text] [Related]

  • 7. [Recommendation for the optimal use of bendamustine in Japan].
    Ohmachi K, Maruyama D, Nisikori M, Suzuki T, Izutsu K.
    Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
    Ujjani C, Cheson B.
    Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
    [Abstract] [Full Text] [Related]

  • 9. Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
    Higo T, Miyagaki T, Nakamura F, Shinohara A, Asano H, Abe H, Senda N, Yoshizaki A, Fukayama M, Kurokawa M.
    Ann Hematol; 2015 Apr; 94(4):683-5. PubMed ID: 25199505
    [No Abstract] [Full Text] [Related]

  • 10. Rituximab plus bendamustine for the treatment of aggressive non-hodgkin lymphoma patients with severe liver impairment.
    Ogura M.
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):188-9. PubMed ID: 23598989
    [No Abstract] [Full Text] [Related]

  • 11. Making advances in first-line chronic lymphocytic leukemia treatment.
    Wierda WG.
    J Clin Oncol; 2012 Sep 10; 30(26):3162-4. PubMed ID: 22869876
    [No Abstract] [Full Text] [Related]

  • 12. Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.
    McCloskey JK, Broome CM, Cheson BD.
    Clin Adv Hematol Oncol; 2013 Mar 10; 11(3):184-8. PubMed ID: 23598988
    [No Abstract] [Full Text] [Related]

  • 13. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
    Friedberg JW.
    Leuk Lymphoma; 2009 Sep 10; 50(9):1399-400. PubMed ID: 19811324
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ.
    Cancer; 2014 Jan 15; 120(2):222-8. PubMed ID: 24122387
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD.
    J Clin Oncol; 2011 Sep 01; 29(25):3389-95. PubMed ID: 21810687
    [Abstract] [Full Text] [Related]

  • 19. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
    Burke JM, van der Jagt RH, Flinn IW, Craig MD, Chen L, Morganroth J, Munteanu MC, MacDonald DA.
    Cancer Chemother Pharmacol; 2015 Jul 01; 76(1):211-6. PubMed ID: 26006703
    [Abstract] [Full Text] [Related]

  • 20. Exacerbation of lymphomatoid papulosis during rituximab therapy.
    McCurdy O, McCormack C, Ritchie D, Prince HM.
    Australas J Dermatol; 2014 Feb 01; 55(1):e1-3. PubMed ID: 23190403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.